Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system

References

• Attama AA, Reichl S, Müller-Goymann CC. (2008). Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm, 355: 307–313.
   PubMed Web of Science ®Google Scholar
• Attama AA, Schicke BC, Müller-Goymann CC. (2006). Further characterization of theobroma oil-beeswax admixtures as lipid matrices for improved drug delivery systems. Eur J Pharm Biopharm, 64: 294–306
   PubMed Web of Science ®Google Scholar
• Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC. (2007). Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization. Eur J Pharm Biopharm, 67: 48–57.
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb Company. New Drug Application for Tequin (Gatifloxacin Tablets and Injections). Environmental Assessment. Center for Drug Evaluation and Research, Website. 2001, Accessed May 31, 2006.
   Google Scholar
• Bunjes H, Westesen K, Koch MHJ. (1996). Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm, 129: 159–173.
   Web of Science ®Google Scholar
• Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR. (1997). Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm, 148: 47– 54.
   Web of Science ®Google Scholar
• Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. (2002). Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm, 238: 241–245.
   PubMed Web of Science ®Google Scholar
• Dingler A, Gohla S. (2002). Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul, 19: 11–16.
   PubMed Web of Science ®Google Scholar
• Freitas C, Müller RH. (1999). Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm, 47: 125–132.
   PubMed Web of Science ®Google Scholar
• Friedrich I, Reichl S, Müller-Goymann CC. (2005). Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int J Pharm, 305: 167–175.
   PubMed Web of Science ®Google Scholar
• Gan L, Gan Y, Zhu C, Zhang X, Zhu J. (2009). Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int J Pharm, 365: 143–149.
   PubMed Web of Science ®Google Scholar
• Gasco MR. (1993). Method for producing solid lipid microspheres having a narrow size distribution, US Patent 5 250 236.
   Google Scholar
• Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Güneri T, Caramella C. (2008). Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm, 364: 76–86.
   PubMed Web of Science ®Google Scholar
• Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces, 45: 167–173.
   PubMed Web of Science ®Google Scholar
• Kalam MA, Sultana Y, Samad A, Ali A, Aqil M, Sharma M, Mishra AK. (2008). Gelrite-based in-vitro gelation ophthalmic drug delivery system of gatifloxacin. J Disp Sci Tech, 29: 89–96.
   Web of Science ®Google Scholar
• Liu J, Gong T, Wang C, Zhong Z, Zhang Z. (2007). Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm, 340: 153–162.
   PubMed Web of Science ®Google Scholar
• Maurice DM. (1970). The transparency of the corneal stroma. Vision Res, 10: 107–108.
   PubMed Web of Science ®Google Scholar
• Mehnert W, zur-Muhlen A, Dingler A, Weyhers H, Muller RH. (1997). Solid Lipid Nanoparticles (SLN)—ein neuartiger Wirkstoff-Carrier fur Kosmetika und Pharmazeutika. II. Wirkstoff-Inkorporation, Freisetzung und Sterilizierbarkeit. Pharm Ind, (59): 511–514.
   Google Scholar
• Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. (2008). Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm, 68: 513–525.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50: 161–177.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mehnert W, Lucks JS, Schwarz C, zur-Muhlen A, Weyhers H, Freitas C, Ruhl D. (1995). Solid lipid nanoparticles (SLN)—an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm, 41: 62–69.
   Web of Science ®Google Scholar
• Muller RH, Runge SA, Ravelli V, Thunemann AF, Mehnert W, Souto EB. (2008). Cyclosporine-loaded solid lipid nanoparticles (SLN): Drug–lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm, 68: 535–544.
   PubMed Web of Science ®Google Scholar
• Muller-Goymann CC. (2004). Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm, 58: 343–356.
   PubMed Web of Science ®Google Scholar
• Niddam-Hildesheim V, Wizel S, Sterimbaum G. (2004). United States Patent. Publication number. US 2004/0192700 A1. Publication date: Sep. 30, 2004.
   Google Scholar
• Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. (2002). Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci, 16: 53–61.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. (2002). Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 23: 3247–3255.
   PubMed Web of Science ®Google Scholar
• Pijls RT, Sonderkamp T, Daube GW, Krebber R, Hanssen HHL, Nuijts RMMA, Koole LH. (2005). Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm, 59: 283–288.
   PubMed Web of Science ®Google Scholar
• Rathore MS, Majumdar DK. (2006). Effect of formulation factors on in-vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS Pharm Sci Tech, 7: E1–E6.
   PubMed Web of Science ®Google Scholar
• Shah AK, Date AA, Joshi MD, Patravale VA. 2007. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int J Pharm, 345: 163–171.
   PubMed Web of Science ®Google Scholar
• Van Ooteghem MM. (1993). In Edman P. (ed.), Biopharmaceutics of Ocular Drug Delivery (pp. 27–41) Boca Raton: CRC Press.
   Google Scholar
• Westesen K, Bunjes H, Koch MHJ. (1997). Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release, 48: 223–236.
   Web of Science ®Google Scholar
• Wissing SA, Kayser O, Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56: 1257–1272.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, Ohtori A. (2005). Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm, 301: 121–128.
   PubMed Web of Science ®Google Scholar